Why Aktis Oncology, Inc. (AKTS) stock fell 10.2% intraday on Monday, November 2, 2026

Aktis Oncology, Inc. (AKTS) traded at $14.3 as of 2:31 PM ET, down 10.23% on Monday, November 2, 2026, on volume of 661,504 shares (1.8× its 3-month average); market value about $800.0M.

AKTS was among the stocks moving 5% or more in an earlier update that day; by the close it was no longer moving that much.

What happened: primary sources

Events Nexqual found for AKTS on Monday, November 2, 2026 or the trading day before (October 30, 2026):

• Nov 2, 2026: One of 14 Biotechnology stocks among the day's biggest losers (PGEN, HELP, DNA, KRYS, TWST, MLYS, MDXG, ASPE, ETRA, BCAX, ABSI, SLS, DFTX, AKTS), with no comparable group among the biggest gainers

These are listed as context. A filing or rating change on the same day is not proof that it caused the move; read the source.

More on AKTS

AKTS stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. Other big moves that day: November 2, 2026.

Sources: SEC EDGAR, Nexqual Earnings Flash, analyst rating changes, Nexqual market data. Built November 4, 2026 at 10:47 UTC. Not investment advice.

Data source: Nexqual. Last updated: November 4, 2026 at 10:47 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt